Overview:

CRISPR-Cas systems constitute the adaptive immune system in bacteria via RNA-guided endonucleases (1,2). This system has been leveraged to create an exemplary genome editing tool with applications in both basic research and therapeutics development (3). PsmCas13b is a CRISPR-Cas effector that belongs to the class 2 subtype VI-B (3). It processes its own CRISPR array with short and long direct repeats, cleaves target RNA, and exhibits collateral RNase activity (3). It has been shown to effectively target and silence distinct mammalian ssRNA viruses (4).

Accession Number:

WP_028912271.1

Formulation:

Recombinant protein stored in 25mM Tris, 300mM NaCl pH7.5 50% glycerol 0.1mM TCEP.

References:

1. Horvath, P., et al. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science, 327(5962):167-170.

2. Morange, M. 2015. What history tells us XXXVII. CRISPR-Cas: The disconvery of an immune system in prokaryotes. J. Biosci. 40(2):221-223.

3. Smargon, A. A., et al. 2017. Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNAse differentially regulated by accessory proteins Csx27 and Csx28. Mol. Cell. 65(4):618-630.

4. Freije, C. A., et al. 2019. Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cell. 76(5):826-837.